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However, the fact that in another study we showed the functional
relevance of the same -786C allele in non-Japanese hypertensive
patients lends further support to the relevance of this polymor-
phism for cardiovascular disease in Caucasians (5).
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Response to Renin-Angiotensin System
Antagonists in Hypertensive Black Subjects
We read with interest the study by Flack et al. (1) which appeared
in the April 2, 2003, issue of the Journal. We commend the
researchers on investigating the effects of aldosterone antagonism
in the black population, who are traditionally underrepresented in
clinical trials. However, we have some concerns regarding the
characteristics of the study subjects.
First of all, we question the investigators’ use of weight, rather
than body mass index (BMI), as an anthropometric measurement.
Data from the Framingham Heart Study indicate that higher BMI
is a major determinant of inadequate blood pressure control with
antihypertensive medications (2). Though not statistically differ-
ent, both male and female subjects in the eplerenone group had
greater body weight than did those in the losartan group. Thus, we
are curious as to whether BMI differed between treatment groups
and, if so, whether these differences may have contributed to the
disparity in results between groups.
Second, the study included participants from both the U.S. and
Africa. The investigators do not report the percentage of black
participants who were from Africa versus those from the U.S. This
information is important in conferring the applicability of the
study findings to blacks in the U.S. Differences in environmental
factors have been reported among populations of African origin,
with higher BMI and greater sodium intake reported among
American blacks compared to African blacks (3). Similar to BMI,
sodium intake is a well-known factor influencing antihypertensive
response to renin-angiotensin system antagonists (4–6). Thus,
whether aldosterone antagonism would produce similar antihyper-
tensive effects in black Americans compared to black Africans is
uncertain.
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REPLY
We appreciate the questions raised by Humma and Adenekan
regarding the potential impact of body mass index (BMI) on the
blood pressure (BP)-lowering differences between eplerenone and
losartan in our recently published study. Also, the relevance of the
BP-lowering obtained in South African blacks to U.S. blacks was
raised.
There were 335 black participants in our trial; 260 (77.6%)
resided in the U.S. and 75 (22.4%) in South Africa. Black
participants were approximately evenly dispersed across treatment
groups with randomization to placebo, eplerenone, and losartan in
the following numbers (U.S. blacks/South African blacks): 1)
placebo (86/24); 2) eplerenone (83/25); and 3) losartan (91/26).
Blood pressure responses (SBP/DBP mm Hg) at 16 weeks (end of
trial) for blacks were: 1) placebo (3.7/4.8); 2) eplerenone
(13.5/10.2); and 3) losartan (5.3/6.0). Among South
African blacks, BP changes were: 1) placebo (1.1/4.1); 2)
eplerenone (11.6/10.1); and 3) losartan (0.8/3.6). The
overall rank-order of BP response was the same among U.S. and
South African blacks, although the absolute magnitude of change
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did appear to differ. Nevertheless, we believe that our reported
findings are relevant to U.S. blacks given the same rank-order of
BP responses within each group as well as the fact that the majority
of black participants were from the U.S.
We agree with Drs. Humma and Adenekan that dietary sodium
intake and body size may potentially confound BP changes to
pharmacological agents. We (1) and others (2,3) have shown that
higher levels of dietary sodium intake attenuates the BP lowering
effect of antihypertensive agents, especially drugs working primar-
ily on the renin-angiotensin-aldosterone-kinin system. The study
participants in our trial were not counseled to restrict dietary
sodium intake nor was urinary sodium excretion measured. Thus,
the effect of dietary sodium by region, ethnic group, or drug
treatment cannot be determined. Conversely, it is plausible that
high levels of dietary sodium may have attenuated the BP lowering
effect of losartan moreso than eplerenone.
We also agree that body size can influence BP change to
pharmacological interventions. In fact, this is an underrecognized
factor influencing treatment responses (4,5). The body weights
(weighted for the proportions of men and women) in the losartan
and eplerenone groups, respectively, were 91.9 kg and 88.7 kg,
which corresponds to a difference of 3.2 kg. When BMI levels are
compared, no difference existed between the eplerenone and
losartan groups in men and only a very small difference in women.
Median BMI levels in women randomized to eplerenone and
losartan, respectively, were 32.1 and 33.8 kg/m2; in men, median
BMI rates for the same two groups were 29.7 and 29.6 kg/m2,
respectively. We do not believe that these very slight differences in
body size account for the BP response differences between
eplerenone and losartan that we reported.
In conclusion, the questions raised are certainly important.
However, we do not believe the relatively modest body size
differences, as determined by any metric, explains our results to any
significant degree. Finally, assuming that high levels of dietary
sodium intake importantly influenced BP responses, our data
suggest that eplerenone lowers BP more robustly in American and
South African blacks than does losartan in high-sodium-
consuming hypertensives.
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Neopterin—A Forgotten Biomarker
In a recent issue of the Journal, Blake and Ridker (1) summarized
findings regarding the prognostic role of C-reactive protein (CRP)
and other inflammatory markers in patients with acute coronary
syndromes (ACS). We would like to point out that the investiga-
tors did not include the role of neopterin in this context. Neopterin
(2), a pteridine derivative and a by-product of the guanosine
triphosphate–biopterin pathway (3), is produced by activated
macrophages and represents a marker of immune activation.
Studies from our group (4) and others (5,6) have shown that
circulating neopterin levels are higher in patients with ACS
compared to patients with a history of myocardial infarction,
patients with stable angina pectoris, or control subjects. High
neopterin levels may be a marker of coronary disease activity, as
suggested by its association with angiographically complex lesions
in patients with unstable angina (7) and its role as a marker of
future cardiovascular events in women with coronary artery disease
(CAD) (8). The prognostic significance of neopterin in ACS
patients has been reported by Auer et al. (9), albeit in a small group
of patients. Preliminary prospective work from our unit has
recently shown that, in patients with CAD, serum neopterin is an
independent predictor of major adverse coronary events at one-
year follow-up (data not published).
Finally, although convincing evidence exists regarding the
prognostic value of inflammatory markers in patients with ACS,
the independent and/or complementary role of different biomar-
kers has not been systematically investigated in large prospective
studies. The ongoing SIESTA (Systemic Inflammation Evaluation
in patients with non–ST-segment elevation Acute coronary syn-
dromes) study (10)—a prospective multicenter trial designed to
assess the relative prognostic role of diverse markers of inflamma-
tion, including, among many others, CRP, neopterin, cell adhesion
molecules, and pregnancy-associated plasma protein A—will help
to elucidate the issue.
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